ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO22

Safety and Efficacy Evaluation of GFB-887, a TRPC5 Channel Inhibitor, in Patients with DN, FSGS, or TR-MCD: Phase 2 Study Design (TRACTION Program)

Session Information

Category: Glomerular Diseases

  • No subcategory defined

Authors

  • Walsh, Liron, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Reilly, John F., Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Cornwall, Caitlin, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Gaich, Gregory A., Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Ge, Tingting, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Gipson, Debbie S., University of Michigan, Ann Arbor, Michigan, United States
  • L Heerspink, Hiddo Jan, University Medical Center Groningen, Groningen, Netherlands
  • Johnson, Leslie, Goldfinch Bio Inc, Cambridge, Massachusetts, United States
  • Trachtman, Howard, NYU Langone Health, New York, New York, United States
  • Tuttle, Katherine R., Providence Washington, Seattle, Washington, United States
  • Czerwiec, Frank S., Goldfinch Bio Inc, Cambridge, Massachusetts, United States
Description

Introduction: Activation of the TRPC5-Rac1 pathway in podocytes is a key driver of podocytopathies such as focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and diabetic nephropathy (DN). Inhibition of the TRPC5 ion channel may be a potential therapeutic target for these podocytopathies. GFB-887 is a small molecule TRPC5 ion channel inhibitor that has been shown in preclinical models to prevent podocyte damage mediated by Rac1 signaling. In a first-in-human study, single doses of GFB-887 were well-tolerated with a favorable PK profile in healthy participants. GFB-887 exhibited dose-dependent reductions in urinary Rac1, indicating that GFB-887 engages TRPC5 in the podocytes and inhibits the TRPC5-Rac1 pathway.
Study Design: This is a phase 2, multicenter, double-blind, placebo-controlled, randomized, multiple ascending dose study designed to characterize the safety, efficacy, PK, and PD of GFB-887 in patients with DN, FSGS, or treatment resistant (TR)-MCD (NCT04387448). The study population will include patients on stable RAAS blockade and/or immunosuppression with residual proteinuria, defined as UPCR ≥ 1.0g/g (FSGS and TR-MCD) or UACR between 150mg/g and 3500mg/g (DN), who remain at high risk of disease progression. Participants in all dose levels will undergo a 4-week screening period, a run-in period of up to 2 weeks, a 12-week treatment period, followed by an 8-week off drug washout period. The first cohort will consist of 8 participants and subsequent cohorts will include a total of 48 participants with DN and 30 participants with either FSGS or TR-MCD. The primary objective is to evaluate the effect of increasing doses of GFB-887 on proteinuria, with the secondary objectives of exploring the safety and PK of GFB-887 after 12 weeks of therapy. Urinary Rac1 will be measured during the study to explore the potential association between urinary Rac1 and GFB-887 treatment responsiveness.
Discussion: Results from this study will provide evidence that blockade of TRPC5-Rac1 pathway with GFB-887 is an effective strategy to treat patients with podocytopathies and guide the next phase of clinical development of GFB-887.

Funding

  • Goldfinch Bio